DarrenRCarpizoMD
General Surgery • Rochester, NYSurgical Oncology (Other than Breast)
Assistant Professor, Surgery, UMDNJ-Robert Wood Johnson Medical School
Dr. Carpizo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
601 Elmwood Ave
Rochester, NY 14642Phone+1 585-275-1984
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Surgery, 1997 - 2006
University of Illinois College of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 1999 - Present
NY State Medical License 2006 - 2025
NJ State Medical License 2008 - 2021- American Board of Surgery Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer Start of enrollment: 2012 Nov 01
- A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC Start of enrollment: 2018 Jun 26
- Pancreatic Cancer Early Detection Consortium Start of enrollment: 2020 Sep 18
Roles: Principal Investigator
Publications & Presentations
PubMed
- 12 citationsThe relationship of perioperative fluid administration to outcomes in colorectal and pancreatic surgery: A review of the literatureOliver S. Eng, Laleh G. Melstrom, Darren R. Carpizo
Journal of Surgical Oncology. 2015-03-15 - 27 citationsZinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer TherapeuticsSamuel Kogan, Darren R. Carpizo
Cancers. 2018-05-29 - 61 citationsSynthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an IonophoreAdam R. Blanden, Xin Yu, Aaron J. Wolfe, John A. Gilleran, David Augeri
Molecular Pharmacology. 2015-05-01
Journal Articles
- Neoadjuvant Chemoradiation Improves Margin Positivity Rates After Pancreaticoduodenectomy in T1 and T2 Resectable Pancreatic Cancer: An Analysis of the National Cancer...Mihir M Shah, Darren R Carpizo, Miral S Grandhi, Russell C Langan, Journal of The American College of Surgeons
Authored Content
- Neoadjuvant Chemoradiation Improves Margin Positivity Rates After Pancreaticoduodenectomy in T1 and T2 Resectable Pancreatic Cancer: An Analysis of the National Cancer DatabaseOctober 2018
Press Mentions
How the Immune System Fails as Cancer ArisesSeptember 12th, 2024- How the Immune System Fails as Cancer ArisesSeptember 12th, 2024
$500K Grant Aids Exploration of Genetic Changes in Pancreatic Cancer for New Treatment TargetsAugust 23rd, 2018- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
